Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator

Robert E. Bristow, F. J. Montz

Research output: Contribution to journalArticle

Abstract

Objective. The aim of this study was to evaluate the utility of the argon beam coagulator (ABC) in achieving optimal (≤1 cm) disease status and facilitating the conversion of optimal but visible disease (0.1-1.0 cm) to microscopic residual disease (complete cytoreduction) among patients with advanced ovarian carcinoma. Methods. All patients undergoing their primary attempt at surgical cytoreduction for Stage IIIB-IV epithelial ovarian carcinoma between October 1, 1997 and June 30, 2000 were identified from the tumor registry database. Data were abstracted retrospectively and included: the size/location of precytoreduction disease, surgical procedures performed, the anatomic regions in which the ABC was used for cytoreduction, the size/location of residual tumor, and the date of last follow-up and disease status. Survival curves were generated using the Kaplan-Meier method, and statistical comparisons were performed using the X2 test, Fisher's exact test, log rank test, and multivariate logistic regression. Results. Forty-five patients were identified (FIGO Stage IIIB=8, Stage IIIC=29, Stage IV=8). Overall, optimal cytoreduction was achieved in 84.4% of patients; 60.0% had only microscopic residual and 24.4% had residual disease 0.1-1.0 cm. The ABC was used to facilitate cytoreduction in 31 patients. Optimal disease status was achieved in 93.6% of cases in which the ABC was used compared with 64.3% for non-ABC cases (P1.0 cm) residual disease (6.3 months, P

Original languageEnglish (US)
Pages (from-to)39-48
Number of pages10
JournalGynecologic Oncology
Volume83
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Argon
Carcinoma
Residual Neoplasm
Registries
Logistic Models
Databases
Survival

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. / Bristow, Robert E.; Montz, F. J.

In: Gynecologic Oncology, Vol. 83, No. 1, 2001, p. 39-48.

Research output: Contribution to journalArticle

Bristow, Robert E. ; Montz, F. J. / Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. In: Gynecologic Oncology. 2001 ; Vol. 83, No. 1. pp. 39-48.
@article{3efe93e01db94e07bfb6bb050d287332,
title = "Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator",
abstract = "Objective. The aim of this study was to evaluate the utility of the argon beam coagulator (ABC) in achieving optimal (≤1 cm) disease status and facilitating the conversion of optimal but visible disease (0.1-1.0 cm) to microscopic residual disease (complete cytoreduction) among patients with advanced ovarian carcinoma. Methods. All patients undergoing their primary attempt at surgical cytoreduction for Stage IIIB-IV epithelial ovarian carcinoma between October 1, 1997 and June 30, 2000 were identified from the tumor registry database. Data were abstracted retrospectively and included: the size/location of precytoreduction disease, surgical procedures performed, the anatomic regions in which the ABC was used for cytoreduction, the size/location of residual tumor, and the date of last follow-up and disease status. Survival curves were generated using the Kaplan-Meier method, and statistical comparisons were performed using the X2 test, Fisher's exact test, log rank test, and multivariate logistic regression. Results. Forty-five patients were identified (FIGO Stage IIIB=8, Stage IIIC=29, Stage IV=8). Overall, optimal cytoreduction was achieved in 84.4{\%} of patients; 60.0{\%} had only microscopic residual and 24.4{\%} had residual disease 0.1-1.0 cm. The ABC was used to facilitate cytoreduction in 31 patients. Optimal disease status was achieved in 93.6{\%} of cases in which the ABC was used compared with 64.3{\%} for non-ABC cases (P1.0 cm) residual disease (6.3 months, P",
author = "Bristow, {Robert E.} and Montz, {F. J.}",
year = "2001",
doi = "10.1006/gyno.2001.6344",
language = "English (US)",
volume = "83",
pages = "39--48",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator

AU - Bristow, Robert E.

AU - Montz, F. J.

PY - 2001

Y1 - 2001

N2 - Objective. The aim of this study was to evaluate the utility of the argon beam coagulator (ABC) in achieving optimal (≤1 cm) disease status and facilitating the conversion of optimal but visible disease (0.1-1.0 cm) to microscopic residual disease (complete cytoreduction) among patients with advanced ovarian carcinoma. Methods. All patients undergoing their primary attempt at surgical cytoreduction for Stage IIIB-IV epithelial ovarian carcinoma between October 1, 1997 and June 30, 2000 were identified from the tumor registry database. Data were abstracted retrospectively and included: the size/location of precytoreduction disease, surgical procedures performed, the anatomic regions in which the ABC was used for cytoreduction, the size/location of residual tumor, and the date of last follow-up and disease status. Survival curves were generated using the Kaplan-Meier method, and statistical comparisons were performed using the X2 test, Fisher's exact test, log rank test, and multivariate logistic regression. Results. Forty-five patients were identified (FIGO Stage IIIB=8, Stage IIIC=29, Stage IV=8). Overall, optimal cytoreduction was achieved in 84.4% of patients; 60.0% had only microscopic residual and 24.4% had residual disease 0.1-1.0 cm. The ABC was used to facilitate cytoreduction in 31 patients. Optimal disease status was achieved in 93.6% of cases in which the ABC was used compared with 64.3% for non-ABC cases (P1.0 cm) residual disease (6.3 months, P

AB - Objective. The aim of this study was to evaluate the utility of the argon beam coagulator (ABC) in achieving optimal (≤1 cm) disease status and facilitating the conversion of optimal but visible disease (0.1-1.0 cm) to microscopic residual disease (complete cytoreduction) among patients with advanced ovarian carcinoma. Methods. All patients undergoing their primary attempt at surgical cytoreduction for Stage IIIB-IV epithelial ovarian carcinoma between October 1, 1997 and June 30, 2000 were identified from the tumor registry database. Data were abstracted retrospectively and included: the size/location of precytoreduction disease, surgical procedures performed, the anatomic regions in which the ABC was used for cytoreduction, the size/location of residual tumor, and the date of last follow-up and disease status. Survival curves were generated using the Kaplan-Meier method, and statistical comparisons were performed using the X2 test, Fisher's exact test, log rank test, and multivariate logistic regression. Results. Forty-five patients were identified (FIGO Stage IIIB=8, Stage IIIC=29, Stage IV=8). Overall, optimal cytoreduction was achieved in 84.4% of patients; 60.0% had only microscopic residual and 24.4% had residual disease 0.1-1.0 cm. The ABC was used to facilitate cytoreduction in 31 patients. Optimal disease status was achieved in 93.6% of cases in which the ABC was used compared with 64.3% for non-ABC cases (P1.0 cm) residual disease (6.3 months, P

UR - http://www.scopus.com/inward/record.url?scp=0034796033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034796033&partnerID=8YFLogxK

U2 - 10.1006/gyno.2001.6344

DO - 10.1006/gyno.2001.6344

M3 - Article

C2 - 11585412

AN - SCOPUS:0034796033

VL - 83

SP - 39

EP - 48

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -